MedKoo Cat#: 407232 | Name: Aloisine A
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Aloisine A is a potent and selective CDK/GSK-3 inhibitor. Aloisine A inhibits cell proliferation by arresting cells in both G1 and G2. IC50 data of Aloisine A: Cdc2 (CDK1)/cyclin B (IC50 = 150nM), Cdk2/cyclin A (IC50 = 120nM), Cdk2/cyclin E (IC50 = 400nM), Cdk5/p25 (IC50 = 200nM), Cdk5/p35 (IC50 = 160nM), and GSK-3α (IC50 = 500nM). Aloisine A also inhibits GSK-3β (IC50 = 650nM) and JNK (c-Jun N-terminal kinase) (IC50~3-10μM). Aloisine A blocks the cell cycle in both G1 and G2 phase.

Chemical Structure

Aloisine A
CAS# 496864-16-5 (A)

Theoretical Analysis

MedKoo Cat#: 407232

Name: Aloisine A

CAS#: 496864-16-5 (A)

Chemical Formula: C16H17N3O

Exact Mass: 267.1372

Molecular Weight: 267.33

Elemental Analysis: C, 71.89; H, 6.41; N, 15.72; O, 5.98

Price and Availability

Size Price Availability Quantity
5mg USD 350.00 2 Weeks
10mg USD 550.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Synonym
Aloisine A
IUPAC/Chemical Name
4-(7-butyl-5H-pyrrolo[2,3-b]pyrazin-6-yl)phenol
InChi Key
PRIGRJPRGZCFAS-UHFFFAOYSA-N
InChi Code
InChI=1S/C16H17N3O/c1-2-3-4-13-14(11-5-7-12(20)8-6-11)19-16-15(13)17-9-10-18-16/h5-10,20H,2-4H2,1H3,(H,18,19)
SMILES Code
CCCCC1=C(C2=CC=C(C=C2)O)NC3=C1N=CC=N3
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 267.33 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Corbel C, Haddoub R, Guiffant D, Lozach O, Gueyrard D, Lemoine J, Ratin M, Meijer L, Bach S, Goekjian P. Identification of potential cellular targets of aloisine A by affinity chromatography. Bioorg Med Chem. 2009 Aug 1;17(15):5572-82. doi: 10.1016/j.bmc.2009.06.024. Epub 2009 Jun 18. PMID: 19596197. 2: Mettey Y, Gompel M, Thomas V, Garnier M, Leost M, Ceballos-Picot I, Noble M, Endicott J, Vierfond JM, Meijer L. Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects. J Med Chem. 2003 Jan 16;46(2):222-36. doi: 10.1021/jm020319p. PMID: 12519061. 3: Wu Q, Kang H, Tian C, Huang Q, Zhu R. Binding Mechanism of Inhibitors to CDK5/p25 Complex: Free Energy Calculation and Ranking Aggregation Analysis. Mol Inform. 2013 Mar;32(3):251-60. doi: 10.1002/minf.201200139. Epub 2013 Feb 27. PMID: 27481520. 4: Rowe J, Greenblatt RJ, Liu D, Moffat JF. Compounds that target host cell proteins prevent varicella-zoster virus replication in culture, ex vivo, and in SCID-Hu mice. Antiviral Res. 2010 Jun;86(3):276-85. doi: 10.1016/j.antiviral.2010.03.007. Epub 2010 Mar 20. PMID: 20307580; PMCID: PMC2866756. 5: Rivest P, Renaud M, Sanderson JT. Proliferative and androgenic effects of indirubin derivatives in LNCaP human prostate cancer cells at sub-apoptotic concentrations. Chem Biol Interact. 2011 Feb 1;189(3):177-85. doi: 10.1016/j.cbi.2010.11.008. Epub 2010 Nov 25. PMID: 21111724.